Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:SLN
- CUSIP: N/A
- Web: silence-therapeutics.com
Capitalization:- Market Cap: £74.25 million
- Outstanding Shares: 69,801,000
Average Prices:- 50 Day Moving Avg: GBX 98.12
- 200 Day Moving Avg: GBX 94.08
- 52 Week Range: GBX 71.88 - GBX 130
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $769,999.00
- Price / Sales: 96.43
- Book Value: GBX 0.78 per share
- Price / Book: 1.37
Profitability:- EBIDTA: ($11,600,000.00)
- Net Margins: -481.43%
- Return on Equity: -13.24%
- Return on Assets: -12.88%
Misc:- Average Volume: 27,800 shs.
Frequently Asked Questions for Silence Therapeutics plc (LON:SLN)
What is Silence Therapeutics plc's stock symbol?
Silence Therapeutics plc trades on the London Stock Exchange (LON) under the ticker symbol "SLN."
When will Silence Therapeutics plc make its next earnings announcement?
Where is Silence Therapeutics plc's stock going? Where will Silence Therapeutics plc's stock price be in 2017?
1 brokerages have issued 12 month target prices for Silence Therapeutics plc's shares. Their forecasts range from GBX 249 to GBX 249. On average, they anticipate Silence Therapeutics plc's share price to reach GBX 249 in the next twelve months. View Analyst Ratings for Silence Therapeutics plc.
Who are some of Silence Therapeutics plc's key competitors?
Some companies that are related to Silence Therapeutics plc include Chromadex Corp (CDXC), Genocea Biosciences (GNCA), OncoMed Pharmaceuticals (OMED), Matinas BioPharma Holdings (MTNB), Oramed Pharmaceuticals (ORMP), Pluristem Therapeutics (PSTI), CTI BioPharma Corp. (CTIC), Vernalis plc (VER), CytRx Corporation (CYTR), Tissue Regenix Group PLC (TRX), ArQule (ARQL), GTx (GTXI), BioLineRx (BLRX), Brainstorm Cell Therapeutics (BCLI), Galectin Therapeutics (GALT), aTyr Pharma (LIFE), Eiger BioPharmaceuticals (EIGR) and Navidea Biopharmaceuticals (NAVB).
Who are Silence Therapeutics plc's key executives?
Silence Therapeutics plc's management team includes the folowing people:
- Ali Mortazavi, Chief Executive Officer, Director
- David Ellam, Chief Financial Officer, Director
- Lars Karlsson, Head of Research and Development, Executive Director
- Mark Cameron, Head of Chemistry
- Stephen B. Parker, Independent Non-Executive Chairman of the Board
- Stuart J.M. Collinson Ph.D., Non-Executive Director
- Alistair William Gray, Non-Executive Director
How do I buy Silence Therapeutics plc stock?
Shares of Silence Therapeutics plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Silence Therapeutics plc's stock price today?
One share of Silence Therapeutics plc stock can currently be purchased for approximately GBX 106.38.
MarketBeat Community Rating for Silence Therapeutics plc (LON SLN)MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Silence Therapeutics plc (LON:SLN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | GBX 249 |
Analysts' Ratings History for Silence Therapeutics plc (LON:SLN)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 1/9/2017 | Canaccord Genuity | Reiterated Rating | Buy | GBX 249 |  |
(Data available from 7/21/2015 forward)
Earnings History for Silence Therapeutics plc (LON:SLN)Earnings History by Quarter for Silence Therapeutics plc (LON SLN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/25/2017 | | | | | | | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Silence Therapeutics plc (LON:SLN)Current Year EPS Consensus Estimate: $-14.900 EPS
Dividend History for Silence Therapeutics plc (LON:SLN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Silence Therapeutics plc (LON:SLN)Insider Trades by Quarter for Silence Therapeutics plc (LON:SLN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/18/2016 | Mortazavi,Ali | Insider | Buy | 160,000 | GBX 125 | £200,000 | |
(Data available from 1/1/2013 forward)
Headline Trends for Silence Therapeutics plc (LON:SLN)
Latest Headlines for Silence Therapeutics plc (LON:SLN)
| Source: |
|
Silence Therapeutics plc (SLN) Chart for Friday, July, 21, 2017
